(Q24658351)

English

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels (English)

0 references

2

Joseph L Witztum

0 references

author name string

Daniel Steinberg

series ordinal

1

0 references

language of work or name

English

0 references

publication date

16 June 2009

0 references

published in

Proceedings of the National Academy of Sciences of the United States of America

0 references

volume

106

0 references

issue

24

0 references

page(s)

9546-7

0 references

cites work

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

A receptor-mediated pathway for cholesterol homeostasis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

7 April 2017

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

28 September 2017

PCSK9: a convertase that coordinates LDL catabolism

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

28 September 2017

Evidence mandating earlier and more aggressive treatment of hypercholesterolemia

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

28 September 2017

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

28 September 2017

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701045

retrieved

28 September 2017

Identifiers

DOI

10.1073/PNAS.0904560106

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2317895

ADS bibcode

2009PNAS..106.9546S

0 references

OpenCitations bibliographic resource ID

2317895

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2317895

PubMed publication ID

19506257

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2317895

ResearchGate publication ID

26275977

0 references

(Q24658351)

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)